The government has launched what it describes as a “landmark” independent review into prescription drug addiction in the UK.
News
NICE backs trial of online programme for depression
The National Institute for Health and Care Excellence has given its backing for an online programme to be trialed on the NHS for the treatment of depression.
Lilly’s Taltz wins EU approval for psoriatic arthritis
Eli Lilly has been given a green light to market Taltz in the European Union as a treatment for psoriatic arthritis.
Teva’s subcutaneous asthma drug fails in PhIII
Teva’s quest to expand approval of its respiratory drug Cinquair/Cinqaero with a new mode of delivery has hit a snag, after two late-stage studies failed to hit their targets.
Rexgenero wins £1.4m grant from Innovate UK
London, UK-based Rexgenero has secured with partners £1.4 million in funding for a £1.8 million project from the UK’s innovation agency Innovate UK, for an industrial research project on the commercial manufacture of its product REX-001.
Astellas bags orphan drug status for AML drug
Astellas’ experimental acute myeloid leukaemia drug gilteritinib has been awarded orphan drug designation by the European Commission.
NICE backs Bayer’s Eylea, Novartis’ Lucentis for sight condition
Cost regulators for NHS-funded therapies in England and Wales have issued updated guidelines for the treatment of wet AMD, which continue to back use of both Bayer’s Eylea and Novartis’ Lucentis, but the GMC says doctors should not fear prescribing Roche’s Avastin off-label if they believe it is clinically appropriate and in the patient’s best interest.
EC OKs Adcetris for CD30-positive cutaneous T-cell lymphoma
The European Commission has extended conditional marketing authorisation for Takeda’s Adcetris to include the treatment of CD30-positive cutaneous T-cell lymphoma (CTCL) following one prior systemic therapy.
Downturn in the number of cancer cases diagnosed as emergency
Some avenues to cancer diagnosis in the UK seem to be improving, with new data from Public Health England showing a shift in the way new cases are detected.
Biosimilar Avastin wins EU approval
European regulators have issued a green light for Amgen and Allergan’s Mvasi, marking the first biosimilar of Roche’s Avastin to be approved in the region.
Biogen ‘optimistic’ for NHS access to Spinraza
Biogen says it is “optimistic” that patients in England and Wales with a rare spinal disorder will get rapid and broad access to Spinraza via the National Health Service in England and Wales.
Sanofi shells out $11.6bn on Bioverativ
Sanofi is fortifying its presence in the field of blood disorders through the purchase of Bioverativ in a deal valued at some $11.6 billion.
Cancer blood tests detects 8 tumour types
Detects 5 kinds of cancer with no current screening tests for average-risk individuals
NHS struggles to fund sustainability projects: report
Money has instead been spent on coping with existing pressures, says National Audit Office report
Sandoz and Biocon to jointly develop ‘multiple’ biosimilars
Novartis’ Sandoz has formed a global partnership with Biocon to develop, manufacture and commercialise multiple biosimilars in immunology and oncology.
